To determine whether administering high dose thoracic radiotherapy, 70 Gy (2 Gy once-daily over 7 weeks) or 61.2 Gy (1.8 Gy once-daily for 16 days followed by 1.8 Gy twice-daily for 9 days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice-daily over 3 weeks) in patients with limited stage small cell lung cancer.
- To compare treatment related toxic effects of thoracic radiotherapy regimens in patients with limited stage small cell lung cancer.
- To compare response rates, failure-free survival and toxicity of thoracic radiotherapy regimens in patients with limited stage small cell lung cancer.
- To compare rates of local relapse, distant metastases and brain metastases with these regimens.
- To compare patient's quality of life between these treatment regimens in terms of their physical symptoms, physical functioning and psychological state.
- To describe the patterns of use of thoracic intensity modulated radiation therapy (IMRT) in patients with limited stage small cell lung cancer.
- To examine blood-based biomarkers of response and resistance to cisplatin and etoposide.
- To evaluate the correspondence between increases in plasma ProGRP concentrations and disease progression/recurrence.
- To evaluate the potential for plasma ProGRP concentrations at baseline, after each cycle of chemotherapy and at first evaluation following completion of chemotherapy to predict PFS and OS.
- To evaluate the correspondence between longitudinal decreases in plasma ProGRP concentrations and clinical response.